Key terms
About SCPH
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SCPH news
Mar 19
1:40am ET
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Mar 14
6:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)
Mar 13
8:15pm ET
Strong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth Prospects
Mar 13
4:50pm ET
scPharmaceuticals files $200M mixed securities shelf
Mar 13
4:08pm ET
scPharmaceuticals reports Q4 EPS (35c) vs. (30c) last year
Mar 11
8:37am ET
Craig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)
Jan 09
1:10am ET
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), Alnylam Pharma (ALNY) and AxoGen (AXGN)
Jan 06
7:45am ET
Strong Buy: scPharmaceuticals’ Furoscix Shows Robust Sales Growth and Solid Financial Health
Jan 05
9:06am ET
Craig-Hallum Remains a Buy on scPharmaceuticals (SCPH)
Jan 05
6:26am ET
Buy Rating for scPharmaceuticals: Furoscix’s Market Traction and Growth Potential Drive Positive Valuation
Jan 04
4:14pm ET
scPharmaceuticals sees Q4 net FUROSCIX revenue $5.9M-M$6.1, consensus $5.32M
No recent press releases are available for SCPH
SCPH Financials
Key terms
Ad Feedback
SCPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SCPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range